ClinicalTrials.gg
RecruitingNCT03753555INSIST-HRMRIUpdated Apr 27, 2026

The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques

A Phase 4 interventional study of Atorvastatin Calcium and Atorvastatin Calcium in Stroke, Ischemic and Atherosclerosis, Cerebral, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by General Hospital of Shenyang Military Region · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2018; still recruiting 7 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region — 16 open to participants now, 16 under way, 1 of them phase 3. Ischemic Stroke · General Hospital of Shenyang Military Region.

Planned enrollment
19th of 27
100 · median 145
Started
2018
with 4 others
Phase 4
5 of 34
2 open now
Primary completion
2027-11
later than 10 of 15 live
Registered
7th of 34
by date

Among the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2018, is one of 5 in phase 4, reaches primary completion later than 10 of the 15 other live ones, and was the 7th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

16 of the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, or all of them as a file.
02

Study summary

Intracranial atherosclerotic disease is the most common cause of ischemic stroke that is directly attributed to the progression or rupture of intracranial high-risk plaque in Asia. Many studies mainly from Euro-American population with a focus on extracranial carotid plaque have fully demonstrated the advantages of intensive statin therapy on stabilizing or reversing plaque burden, reversing plaque composition presenting that lipid-rich necrotic core (LRNC) is gradually replaced by fibrous tissue, and even reversing pattern of arterial remodeling to reduce the occurrence of cerebrovascular events. Yet, direct evidence of the effect of intensive statin therapy on intracranial atherosclerotic plaques is lacking and the effect of statin intensity and duration on intracranial plaque burden and composition is still unclear. High resolution magnetic resonance imaging (HRMRI) is a new and non-invasive technique that enable to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery. Based on above discussion, the investigators conduct this study to further determine the effect of intensive statin in ischemic stroke with intracranial atherosclerotic plaques.

03

Conditions studied

  • Stroke, Ischemic
  • Atherosclerosis, Cerebral
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient age between 18-80 years
  2. Time of onset: within 1 week
  3. NIHSS score ≤12
  4. Acute ischemic stroke confirmed by head CT or MRI
  5. Premorbid mRS ≤1
  6. The degree of stenosis of carotid artery, vertebral artery and intracranial portion of internal carotid artery on the lesion side \<50%
  7. The culprit plaque or possible culprit plaque with plaque burden of 40% or more found by HRMRI in the proximal part of the middle cerebral artery M1 segment or basilar artery of ipsilateral lesion
  8. Signed

Exclusion criteria

Exclusion Criteria:

  1. Intracranial hemorrhage found by head CT
  2. Stroke attributable to cardioembolic origin (atrial fibrillation, valvular heart disease, aortic arch atherosclerosis)
  3. Severe hepatic or renal dysfunction
  4. Pregnant females
  5. Abnormal elevation of creatine phosphokinase
  6. Expected stent angioplasty
  7. Blood sugar is out of control
  8. Receiving statins within 1 month before onset
  9. Obstinate hypertension with more than 140/90 mmHg after medication
  10. Not willing and able to comply with scheduled visits, lifestyle guidelines, treatment plan, laboratory tests, and other study procedures
  11. Unsuitable for this clinical studies assessed by researcher
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Routine-dose statin group

    Routine-dose statin group will be gaven the treatment of atorvastatin 20mg Qd for 12 months

    Drug: Atorvastatin Calcium

  • Experimental
    high-dose statin or PCSK9 inhibitor group

    high-dose statin group will be gaven the treatment of atorvastatin 40-80mg Qd till 6 months at the moment the subjects will be followed up to determine plaques status by HRMRI examination, among which the subjects presenting culprit plaque progression with the significant increasing of plaque burden including intraplaque hemorrhage will be again randomized into two groups at a ratio of 1:1 as followed: atorvastatin-probucol group will be administrated atorvastatin 40-80mg Qd plus probucol 0.5g Bid till 12 months, the other group will maintain the original scheme till 12 months. PCSK9 inhibitor group will receive the subcutaneous injection of Evolocumab (140mg, 2 / month) for one year.

    Drug: Atorvastatin Calcium · Drug: Probucol · Drug: PCSK9 inhibitor

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in remodeling index after the statin treatment

    remodeling index: crimed vessel area/normal vessel area on high-resolution MRI

    Time frame: baseline, 6 months, 12 months after treatment

  2. Changes in plaque burden after the statin treatment

    plaque burden: crimed vessel wall area/crimed vessel area on high-resolution MRI

    Time frame: baseline, 6 months, 12 months after treatment

  3. Changes plaque composition in after the statin treatment

    plaque composition: lipid core and fiber tissue of plaque on high-resolution MRI

    Time frame: baseline, 6 months, 12 months after treatment

Secondary outcomes

  1. level of serum bio-markers compared with baseline

    Serum level of LDL、hs-CRP、sLOX1 and oxLDL

    Time frame: 6 months

  2. level of serum bio-markers compared with baseline

    Serum level of LDL、hs-CRP、sLOX1 and oxLDL

    Time frame: 12 months

  3. mRS (0-2)

    proportion of mRS (0-2)

    Time frame: 6 months

  4. mRS (0-2)

    proportion of mRS (0-2)

    Time frame: 12 months

  5. vascular events

    incidence of Transient ischemic attack, stroke or other vascular events

    Time frame: 6 months

  6. vascular events

    incidence of Transient ischemic attack, stroke or other vascular events

    Time frame: 12 months

  7. abnormal test data

    incidence of abnormal liver function or muscle enzyme levels

    Time frame: 12 months

  8. any adverse event

    incidence of adverse event

    Time frame: 12 months

  9. death of any causes

    proportion of death

    Time frame: 12months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2018 (actual). Primary completion is estimated for Nov 2027, 107 months after the start.

Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 107 months is above that.

Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2018
First posted
Nov 27, 2018
StartActual
Dec 1, 2018
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03753555
Lead sponsor
General Hospital of Shenyang Military Region
Responsible party
Hui-Sheng Chen (Department Chairman, General Hospital of Shenyang Military Region) — Principal investigator
First posted
Nov 27, 2018
Start date
Dec 1, 2018
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Apr 27, 2026

Study contacts

Xinhong Wang, Doctor
Contact
450341972@qq.com
15309885658 ext. 024-28897512
Yu Cui, Master
Contact
314486939@qq.com
18842398646 ext. 024-28897512
Huisheng Chen, Doctor
study chair · Neurology Department

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Probucol · PCSK9 Inhibitor

Start the discussion